PPARA agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

In conclusion, our studies suggest that promoting PPARA activity to enhance mitochondrial metabolism may be a useful therapeutic strategy for ADPKD.
PMID: 28903946 [PubMed - as supplied by publisher]

Source: Am J Physiol Renal P... - September 13, 2017 Category: Urology & Nephrology Authors: Lakhia R, Yheskel M, Flaten A, Quittner-Strom EB, Holland WL, Patel V Tags: Am J Physiol Renal Physiol Source Type: research